Addressing Unmet Needs in Mantle Cell Lymphoma With CAR T Therapy: Anita Kumar, MD

Video

The medical oncologist from Memorial Sloan Kettering Cancer Center discussed efforts made to address areas of unmet need in mantle cell lymphoma.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Anita Kumar, MD, medical oncologist, Regional Care Network Medical Site Director, MSK Basking Ridge, Memorial Sloan Kettering Cancer Center, about efforts made to address areas of unmet need in mantle cell lymphoma.

Kumar discussed how challenges still exist in treating patients with MCL who harbor p53 mutations, blastic disease, and primary refractory disease, as well as efforts are currently underway to identify which therapies may have activity in these subsets. Recently, data with brexucabtagene autoleucel (formerly KTE-X19; Tecartus) suggest that the CAR T-cell therapy can improve efficacy, even in high-risk subsets, Kumar says.

Because remissions are often shorter with standard chemotherapy/immunotherapy regimens, as well as novel targeted therapies, patients who experience early relapse, harbor p53 mutations, or have blastic disease should be referred to a specialized center with access to CAR T-cell therapy, Kumar concludes.

Related Videos
Daniel Hart, PhD, on CRISPR-Mediated, In Vivo Epigenomic Activation
Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Related Content
© 2024 MJH Life Sciences

All rights reserved.